Antares Pharma, Inc. Sustainability Profile
Antares Pharma, Inc., a leading player in the pharmaceutical industry, is headquartered in the United States. Founded in 1978, the company has established itself as a pioneer in the development of innovative drug delivery systems, particularly in the areas of injectable pharmaceuticals. With a focus on enhancing patient compliance and improving therapeutic outcomes, Antares Pharma offers a range of unique products, including its proprietary auto-injector technology and transdermal delivery systems. The company has achieved significant milestones, including partnerships with major pharmaceutical firms and the successful launch of several key products. Antares Pharma's commitment to innovation and quality has positioned it as a trusted name in the market, making substantial contributions to the fields of endocrinology, pain management, and other therapeutic areas.
DitchCarbon Score
How does Antares Pharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Antares Pharma, Inc.'s score of 25 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Antares Pharma, Inc.'s reported carbon emissions
Antares Pharma, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Halozyme Therapeutics, Inc., which may influence its climate-related initiatives and reporting practices. While Antares Pharma has not established specific reduction targets or commitments under the Science Based Targets initiative (SBTi), it is important to note that the company is part of a broader industry context that increasingly prioritises sustainability and carbon footprint reduction. The lack of direct emissions data suggests that Antares Pharma may be in the early stages of developing its climate strategy. As a subsidiary, Antares Pharma may align its environmental goals with those of Halozyme Therapeutics, Inc., which could include participation in initiatives such as the Carbon Disclosure Project (CDP). However, specific details regarding emissions reduction initiatives or climate pledges have not been disclosed. In summary, while Antares Pharma, Inc. does not currently report emissions data or specific climate commitments, its affiliation with Halozyme Therapeutics, Inc. may provide a framework for future sustainability efforts.
How Carbon Intensive is Antares Pharma, Inc.'s Industry?
How Carbon Intensive is Antares Pharma, Inc.'s Location?
Antares Pharma, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Antares Pharma, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
